Clinical trials: Vascular And Immunologic Diseases
Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
This study is being done to examine the safety and effectiveness of pacritinib as a possible treatment for participants with Waldenström macroglobulinemia (WM).
- Conditions
- Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
- Trial name
- NCT06986174
- Testing
- Pacritinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Shayna Sarosiek, MD
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the…
- Conditions
- Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Bladder Carcinoma, Advanced Breast Carcinoma
- Trial name
- NCT05969860
- Testing
- Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment
- Where
- 2 sites in United States
- Volunteers
- 220 people
- Sponsor
- Mayo Clinic
Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
This phase Ib trial studies the side effects of combination chemotherapy and donor stem cell transplant followed by ixazomib citrate maintenance therapy in treating patients with multiple myeloma that has returned after a period…
- Trial name
- NCT02504359
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- OHSU Knight Cancer Institute
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Chronic Spontaneous Urticaria
A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria
The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria
- Trial name
- NCT05368285
- Testing
- barzolvolimab
- Where
- 56 sites in United States, Bulgaria and 7 more
- Volunteers
- 208 people
- Sponsor
- Celldex Therapeutics
Relapsed/Refractory Multiple Myeloma
A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR269A, with or without nirogacestat, in adults with…
- Trial name
- NCT04171843
- Testing
- PBCAR269A, Fludarabine, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Precision BioSciences, Inc.
Chronic Spontaneous Urticaria
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
The purpose of this study is to investigate the use of benralizumab is effective in the treatment of chronic spontaneous urticaria (CSU) who are symptomatic despite the use of antihistamines.
- Trial name
- ARROYO (NCT04612725)
- Testing
- Benralizumab
- Where
- 40 sites in United States, Bulgaria and 5 more
- Volunteers
- 159 people
- Sponsor
- AstraZeneca
Multiple Myeloma
89Zr-labeled NY008 PET Imaging in Patients
This is a single arm study to evaluate the safety and biodistribution of 89Zr-labeled NY008 PET Imaging in patients with multiple myeloma
- Trial name
- NCT05655676
- Testing
- 89Zr-NY008
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Affiliated Hospital of Jiangnan University
Multiple Myeloma
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability
Multiple myeloma represents the second most common hematological malignancy.VELCADE is a small molecule to treat human malignancies.
- Trial name
- NCT00257114
- Testing
- bortezomib
- Where
- United States
- Sponsor
- Millennium Pharmaceuticals, Inc.
Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma.
- Trial name
- NCT00003615
- Testing
- denileukin diftitox
- Where
- 10 sites in United States
- Volunteers
- 77 people
- Sponsor
- Eastern Cooperative Oncology Group
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Cardiovascular Complications
Vascular Complications in Children From T1D Diagnosis
Cardiovascular disease is a complication of type 1 diabetes (T1D), a life-long disease, usually diagnosed in childhood. The goal of this project is to determine the timing and factors leading to vascular damage in children from…
- Conditions
- Type 1 Diabetes, Cardiovascular Complications, Child, Adolescent
- Trial name
- NCT05790785
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Multiple Myeloma, Neoplasm, Plasma Cell
Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma
This study will find the maximum tolerated dose (MTD) of CYNK-001 which contain NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given post Autologous Stem Cell Transplant (ASCT).
- Conditions
- Multiple Myeloma, Neoplasm, Plasma Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT04309084
- Testing
- CYNK-001
- Where
- 4 sites in United States
- Volunteers
- 29 people
- Sponsor
- Celularity Incorporated
Type 1 Diabetes
Effects of Acipimox on Insulin Action, Vascular Function, and Muscle Function in Type 1 Diabetes
Insulin resistance (IR) is an important contributor to increased cardiovascular disease risk in type 1 diabetes (T1D). Non-esterified fatty acid elevation is a significant contributor to IR in T1D and may be a target of…
- Trial name
- AcT1 (NCT01816165)
- Testing
- Acipimox
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Multiple Myeloma and Plasma Cell Neoplasm
Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Drugs used in chemotherapy such as cyclophosphamide and dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00609167
- Testing
- bortezomib, cyclophosphamide, dexamethasone
- Where
- 2 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Mayo Clinic
Multiple Myeloma, Venous Thromboembolism (VTE)
Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple Myeloma
The goal of this clinical trial is to compare the efficacy and safety of aspirin versus rivaroxaban for thromboprophylaxis in newly diagnosed multiple myeloma patients receiving immunomodulatory drug (IMiD)-based therapy.
- Trial name
- NCT07907211
- Testing
- Aspirin, Rivaroxaban
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chen Lijuan
Churg-Strauss Syndrome
Immuno-ablation With Chemoimmunoradiation and Autologous Stem Cell Transplant for Churg-Strauss Syndrome
Churg-Strauss syndrome is a rare autoimmune inflammatory disease affecting medium- and small-sized blood vessels, causing asthma, abnormalities of the blood, lung diseases, and neuropathy.
- Trial name
- NCT02728271
- Testing
- HPC cell infusion
- Volunteers
- 1 people
- Sponsor
- Mounzer Agha
Uremia; Chronic, Cardiovascular Diseases (CVD)
Prevention and Management of Cardiovascular and Cerebrovascular Complications in Maintenance Hemodialysis (MHD) Patients
Background and Purpose: This clinical study aims to explore and validate two innovative treatment strategies to address two major challenges faced by patients on maintenance hemodialysis (uremia): the high incidence of…
- Conditions
- Uremia; Chronic, Cardiovascular Diseases (CVD), Cerebrovascular Disorders, Intradialytic Hypotension
- Trial name
- NCT07335471
- Testing
- Continuous High-Glucose Infusion and Regular Hemoperfusion in Maintenance Hemodialysis
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Suzhou Municipal Hospital of Anhui Province
Relapsed or Refractory Multiple Myeloma (RRMM)
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma
A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing F182112 with Standard of Care in Patients with Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07579234
- Testing
- F182112 single-agent, Pomalidomide + Bortezomib + Dexamethasone (PVd) or Selinexor + Bortezomib + Dexamethasone (SVd)
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Waldenstrom's Macroglobulinemia
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
The purpose of this research study is to test the safety of the combination of everolimus, rituximab and bortezomib. Everolimus is a drug that works by preventing cells in your body from growing and dividing.
- Trial name
- NCT01125293
- Testing
- Everolimus, Rituximab, Bortezomib
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Dana-Farber Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.